{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T00:24:28Z","timestamp":1715387068531},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,10]]},"DOI":"10.7759\/cureus.60049","type":"journal-article","created":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:26:38Z","timestamp":1715361998000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Combination Therapies for Autoimmune Hepatitis: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Essam","family":"Rashad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa M","family":"Moazam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raheel","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noha","family":"El Eraky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Sohail S","family":"Mirza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhana","family":"Nazmin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23584","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns MP","year":"2010","unstructured":"Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, Vierling JM. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010, 51:2193-213. 10.1002\/hep.23584","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000347211","article-title":"Autoimmune hepatitis","volume":"31","author":"Strassburg CP","year":"2013","unstructured":"Strassburg CP. Autoimmune hepatitis. Dig Dis. 2013, 31:155-63. 10.1159\/000347211","journal-title":"Dig Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)62163-1","article-title":"Autoimmune hepatitis","volume":"9902","author":"Heneghan MA","year":"2013","unstructured":"Heneghan MA, Yeoman AD, Verma S, et al.. Autoimmune hepatitis. Lancet. 2013, 9902:1433-44. 10.1016\/S0140-6736(12)62163-1","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2011.09.008","article-title":"Liver transplantation in autoimmune liver diseases","volume":"25","author":"Ilyas JA","year":"2011","unstructured":"Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol. 2011, 25:765-82. 10.1016\/j.bpg.2011.09.008","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref5","article-title":"Liver, blood proteins and food proteins","volume":"12","author":"Waldenstrom J","year":"1952","unstructured":"Waldenstrom J. Liver, blood proteins and food proteins. Dtsch Z Verdau Stoffwechselkr. 1952, 12:113-21.","journal-title":"Dtsch Z Verdau Stoffwechselkr"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: International Autoimmune Hepatitis Group","volume":"18","author":"Johnson PJ","year":"1993","unstructured":"Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993, 18:998-1005. 10.1002\/hep.1840180435","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0168-8278","article-title":"International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis","volume":"1","author":"Alvarez F","year":"1999","unstructured":"Alvarez F, Berg PA, Bianchi FB, et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol. 1999, 1:929-38. 10.1016\/s0168-8278","journal-title":"J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1080\/00365529850166284","article-title":"Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population","volume":"33","author":"Boberg KM","year":"1998","unstructured":"Boberg KM, Aadland E, Jahnsen J, Raknerud N, Stiris M, Bell H. Incidence and prevalence of primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis in a Norwegian population. Scand J Gastroenterol. 1998, 33:99-103. 10.1080\/00365529850166284","journal-title":"Scand J Gastroenterol"},{"key":"ref9","article-title":"Incidence of adult form of autoimmune hepatitis in Valencia (Spain)","volume":"72","author":"Primo J","year":"2009","unstructured":"Primo J, Maroto N, Mart\u00ednez M, et al.. Incidence of adult form of autoimmune hepatitis in Valencia (Spain). Acta Gastroenterol Belg. 2009, 72:402-6.","journal-title":"Acta Gastroenterol Belg"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.06019.x","article-title":"Prevalence of autoimmune liver disease in Alaska Natives","volume":"97","author":"Hurlburt KJ","year":"2002","unstructured":"Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV. Prevalence of autoimmune liver disease in Alaska Natives. Am J Gastroenterol. 2002, 97:2402-7. 10.1111\/j.1572-0241.2002.06019.x","journal-title":"Am J Gastroenterol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s1089-3261(02)00019-3","article-title":"Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features","volume":"6","author":"McFarlane IG","year":"2002","unstructured":"McFarlane IG. Autoimmune hepatitis: diagnostic criteria, subclassifications, and clinical features. Clin Liver Dis. 2002, 6:605-21. 10.1016\/s1089-3261(02)00019-3","journal-title":"Clin Liver Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03782.x","article-title":"Autoimmune hepatitis in the elderly","volume":"96","author":"Schramm C","year":"2001","unstructured":"Schramm C, Kanzler S, zum B\u00fcschenfelde KH, Galle PR, Lohse AW. Autoimmune hepatitis in the elderly. Am J Gastroenterol. 2001, 96:1587-91. 10.1111\/j.1572-0241.2001.03782.x","journal-title":"Am J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21074","article-title":"Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly","volume":"43","author":"Czaja AJ","year":"2006","unstructured":"Czaja AJ, Carpenter HA. Distinctive clinical phenotype and treatment outcome of type 1 autoimmune hepatitis in the elderly. Hepatology. 2006, 43:532-8. 10.1002\/hep.21074","journal-title":"Hepatology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2006.04.007","article-title":"Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre","volume":"45","author":"Al-Chalabi T","year":"2006","unstructured":"Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol. 2006, 45:575-83. 10.1016\/j.jhep.2006.04.007","journal-title":"J Hepatol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.05272.x","article-title":"Autoimmune hepatitis in African Americans: presenting features and response to therapy","volume":"96","author":"Lim KN","year":"2001","unstructured":"Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: presenting features and response to therapy. Am J Gastroenterol. 2001, 96:3390-4. 10.1111\/j.1572-0241.2001.05272.x","journal-title":"Am J Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21884","article-title":"The impact of ethnicity on the natural history of autoimmune hepatitis","volume":"46","author":"Verma S","year":"2007","unstructured":"Verma S, Torbenson M, Thuluvath PJ. The impact of ethnicity on the natural history of autoimmune hepatitis. Hepatology. 2007, 46:1828-35. 10.1002\/hep.21884","journal-title":"Hepatology"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(92)90041-v","article-title":"HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients","volume":"103","author":"Seki T","year":"1992","unstructured":"Seki T, Ota M, Furuta S, et al.. HLA class II molecules and autoimmune hepatitis susceptibility in Japanese patients. Gastroenterology. 1992, 103:1041-7. 10.1016\/0016-5085(92)90041-v","journal-title":"Gastroenterology"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1998.tb00674.x","article-title":"Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis","volume":"13","author":"Nakamura K","year":"1998","unstructured":"Nakamura K, Yoneda M, Yokohama S, et al.. Efficacy of ursodeoxycholic acid in Japanese patients with type 1 autoimmune hepatitis. J Gastroenterol Hepatol. 1998, 13:490-5. 10.1111\/j.1440-1746.1998.tb00674.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-017-4728-2","article-title":"Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis","volume":"62","author":"Purnak T","year":"2017","unstructured":"Purnak T, Efe C, Kav T, Wahlin S, Ozaslan E. Treatment response and outcome with two different prednisolone regimens in autoimmune hepatitis. Dig Dis Sci. 2017, 62:2900-7. 10.1007\/s10620-017-4728-2","journal-title":"Dig Dis Sci"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1159\/000329805","article-title":"Therapeutic strategies for autoimmune hepatitis","volume":"29","author":"Manns MP","year":"2011","unstructured":"Manns MP, Strassburg CP. Therapeutic strategies for autoimmune hepatitis. Dig Dis. 2011, 29:411-5. 10.1159\/000329805","journal-title":"Dig Dis"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.10.017","article-title":"Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome","volume":"44","author":"Chazouill\u00e8res O","year":"2006","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, Rosmorduc O, Poupon R. Long term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. J Hepatol. 2006, 44:400-6. 10.1016\/j.jhep.2005.10.017","journal-title":"J Hepatol"},{"key":"ref22","article-title":"Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis","volume":"57","author":"Ozaslan E","year":"2010","unstructured":"Ozaslan E, Efe C, Akbulut S, Purnak T, Savas B, Erden E, Altiparmak E. Therapy response and outcome of overlap syndromes: autoimmune hepatitis and primary biliary cirrhosis compared to autoimmune hepatitis and autoimmune cholangitis. Hepatogastroenterology. 2010, 57:441-6.","journal-title":"Hepatogastroenterology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280203","article-title":"Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy","volume":"28","author":"Chazouill\u00e8res O","year":"1998","unstructured":"Chazouill\u00e8res O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology. 1998, 28:296-301. 10.1002\/hep.510280203","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111\/j.1872-034X.2011.00844.x","article-title":"Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan","volume":"41","author":"Tanaka A","year":"2011","unstructured":"Tanaka A, Harada K, Ebinuma H, et al.. Primary biliary cirrhosis - autoimmune hepatitis overlap syndrome: a rationale for corticosteroids use based on a nation-wide retrospective study in Japan. Hepatol Res. 2011, 41:877-86. 10.1111\/j.1872-034X.2011.00844.x","journal-title":"Hepatol Res"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4254%2Fwjh.v6.i6.410","article-title":"Management of autoimmune hepatitis: focus on pharmacologic treatments beyond corticosteroids","volume":"6","author":"Moura MC","year":"2014","unstructured":"Moura MC. Management of autoimmune hepatitis: focus on pharmacologic treatments beyond corticosteroids. World J Hepatol. 2014, 6:410-10. 10.4254%2Fwjh.v6.i6.410","journal-title":"World J Hepatol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.5114\/pg.2015.52566","article-title":"Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children","volume":"11","author":"Pniewska A","year":"2016","unstructured":"Pniewska A, Sobolewska-Pilarczyk M, Paw\u0142owska M. Evaluation of the effectiveness of treatment with prednisone and azathioprine of autoimmune hepatitis in children. Prz Gastroenterol. 2016, 11:18-23. 10.5114\/pg.2015.52566","journal-title":"Prz Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients","volume":"55","author":"Zachou K","year":"2011","unstructured":"Zachou K, Gatselis N, Papadamou G, Rigopoulou EI, Dalekos GN. Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-na\u00efve patients. J Hepatol. 2011, 55:636-46. 10.1016\/j.jhep.2010.12.032","journal-title":"J Hepatol"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3350%2Fcmh.2015.21.2.150","article-title":"Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes","volume":"21","author":"Park Y","year":"2015","unstructured":"Park Y, Cho Y, Cho EJ, et al.. Retrospective analysis of autoimmune hepatitis-primary biliary cirrhosis overlap syndrome in Korea: characteristics, treatments, and outcomes. Clin Mol Hepatol. 2015, 21:150. 10.3350%2Fcmh.2015.21.2.150","journal-title":"Clin Mol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.06.00030206","article-title":"Sildenafil treatment for portopulmonary hypertension","volume":"28","author":"Reichenberger F","year":"2006","unstructured":"Reichenberger F, Voswinckel R, Steveling E, et al.. Sildenafil treatment for portopulmonary hypertension. Eur Respir J. 2006, 28:563-7. 10.1183\/09031936.06.00030206","journal-title":"Eur Respir J"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.2165\/00063030-200418010-00006","article-title":"Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C","volume":"18","author":"Malaguarnera M","year":"2004","unstructured":"Malaguarnera M, Guccione N, Musumeci S, Brogna A, Motta M, Di Fazio I. Intravenous immunoglobulin plus interferon-alpha in autoimmune hepatitis C. BioDrugs. 2004, 18:63-70. 10.2165\/00063030-200418010-00006","journal-title":"BioDrugs"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander M","year":"2019","unstructured":"Friedlander M, Meniawy T, Markman B, et al.. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial. Lancet Oncol. 2019, 20:1306-15. 10.1016\/s1470-2045(19)30396-1","journal-title":"Lancet Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1001\/jama.270.21.2598","article-title":"Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group","volume":"270","author":"Guyatt GH","year":"1993","unstructured":"Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature. II. How to use an article about therapy or prevention. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA. 1993, 270:2598-601. 10.1001\/jama.270.21.2598","journal-title":"JAMA"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2010.06579.x","article-title":"Treatment of autoimmune hepatitis: a review of current and evolving therapies","volume":"26","author":"Jothimani D","year":"2011","unstructured":"Jothimani D, Cramp ME, Mitchell JD, Cross TJ. Treatment of autoimmune hepatitis: a review of current and evolving therapies. J Gastroenterol Hepatol. 2011, 26:619-27. 10.1111\/j.1440-1746.2010.06579.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers MM","year":"2010","unstructured":"Lamers MM, van Oijen MG, Pronk M, Drenth JP. Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials. J Hepatol. 2010, 53:191-8. 10.1016\/j.jhep.2010.01.037","journal-title":"J Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1155%2F2013%2F490731","article-title":"Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis","volume":"2013","author":"Zhang Y","year":"2013","unstructured":"Zhang Y, Lu J, Dai W, et al.. Combination therapy of ursodeoxycholic acid and corticosteroids for primary biliary cirrhosis with features of autoimmune hepatitis: a meta-analysis. Gastroenterol Res Pract. 2013, 2013:1-9. 10.1155%2F2013%2F490731","journal-title":"Gastroenterol Res Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/241860-efficacy-of-combination-therapies-for-autoimmune-hepatitis-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,10]],"date-time":"2024-05-10T17:26:42Z","timestamp":1715362002000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/241860-efficacy-of-combination-therapies-for-autoimmune-hepatitis-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,10]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.60049","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,10]]}}}